Literature DB >> 2438667

Distribution of label after intrathecal administration of 125I-substance P in the rat.

R A Cridland, K Yashpal, V V Romita, S Gauthier, J L Henry.   

Abstract

Despite the widespread use of the intrathecal route for the administration of neuroactive agents, little is known about the penetration of these agents into the spinal cord. In the present study, 125I-substance P was injected via a spinal catheter to the thoracic or sacro-coccygeal spinal cord in the rat (350-400 g) anesthetized with urethane (2.5 g/kg). Spinal cords were removed rapidly at 1 or 10 min after injection and immediately frozen in CCl2F2. Frozen sections, 20 micron thick, were cut and mounted for autoradiography. Autoradiographs of transverse sections demonstrated that the label penetrated 700 to 1800 micron from the surface of the spinal cord at both levels. In longitudinal sections, this penetration extended about 0.5 cm rostrally and caudally from the site of injection. Serial autoradiographs of transverse sections showed a similar penetration rostro-caudally. In addition, venous blood samples were taken at 1, 6, 11 and 16 min after injection of the labelled peptide. Quantification of the radioactivity in the samples revealed that 0.8 to 3.5% of the total CPM injected had passed into the general circulation at these times. These data indicate that after intrathecal administration of radiolabelled substance P, the label penetrates into the grey matter of the spinal cord to presumed sites of action. They also suggest that the rostro-caudal extent of penetration is more localized than suggested from earlier studies which looked only at levels of radioactivity in pieces of whole spinal cord. Finally, our study has indicated that passage of label into the circulation is negligible at least for substance P.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438667     DOI: 10.1016/0196-9781(87)90092-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats.

Authors:  F Cloutier; R Couture
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Role of spinal V1a receptors in regulation of arterial pressure during acute and chronic osmotic stress.

Authors:  Britta Veitenheimer; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-01       Impact factor: 3.619

3.  Pharmacologic and autoradiographic evidence for an up-regulation of kinin B(2) receptors in the spinal cord of spontaneously hypertensive rats.

Authors:  Frank Cloutier; Hudson de Sousa Buck; Brice Ongali; Réjean Couture
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  Evidence for a GABA(B) receptor component in the spinal action of Substance P (SP) on arterial blood pressure in the awake rat.

Authors:  Jonathan Brouillette; Réjean Couture
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Cardiovascular effects of intrathecal administration of agents active at 5-hydroxytryptamine1-receptors in the rat: modulation by substance P and a substance P antagonist.

Authors:  K Gradin; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Cardiovascular effects of intrathecal administration of substance P in the rat: interactions with serotonergic mechanisms.

Authors:  K Gradin; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1992

7.  Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.

Authors:  Frank Cloutier; Brice Ongali; Kathleen Deschamps; Jonathan Brouillette; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 8.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.